Overview

Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. The fear network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there is little information on how escitalopram affects the fear network. The specific aim of this study is to test the following hypotheses using 18F-FDG positron emission tomography (PET) 1. Patients with panic disorder will show abnormal activity of the fear network compared to healthy comparison subjects. 2. Patients with panic disorder will show normalized activity of the fear network after 12-weeks of treatment with escitalopram. 3. The changes of fear work after the treatment will be associated with psychological variables and neurohormones.
Phase:
Phase 4
Details
Lead Sponsor:
Samsung Medical Center
Collaborator:
H. Lundbeck A/S
Treatments:
Citalopram
Dexetimide